AMGN

Amgen Inc. News Headlines

$144.01
*  
1.99
1.4%
Get AMGN Alerts
*Delayed - data as of Sep. 19, 2014  -  Find a broker to begin trading AMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
9/19/2014 6:25:00 PM - Zacks.com

3 Biotechs Investors Should Watch
9/19/2014 1:49:27 PM - Motley Fool

XLV, JNJ, AMGN, BMY: ETF Inflow Alert
9/19/2014 11:00:14 AM - BNK Invest

Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
9/18/2014 5:35:00 PM - Zacks.com

Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
9/17/2014 7:15:00 PM - Zacks.com

UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
9/17/2014 6:40:00 PM - Zacks.com

Why Amgen Inc.'s Stock Is up 23% in 2014
9/17/2014 1:46:02 PM - Motley Fool

3 Hot Ways to Play the Biotechnology Bonanza
9/17/2014 10:52:17 AM - InvestorPlace Media

Alexion Names David Hallal COO - Quick Facts
9/17/2014 7:53:00 AM - RTT News

Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
9/16/2014 5:00:00 PM - Zacks.com

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
9/16/2014 3:30:00 PM - Zacks.com

Advice To The Hesitant Investor - Buy. Or Do Not. There Is No Try
9/16/2014 6:01:00 AM - Seeking Alpha

Amgen: Phase 2 Study Of Romosozumab Shows Increases In Bone Mineral Density
9/15/2014 5:02:00 PM - RTT News

Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
9/15/2014 4:45:00 PM - Zacks.com

Amgen Presents Phase 3 Ivabradine Data On Chronic Heart Failure Treatment
9/14/2014 9:22:00 PM - RTT News

Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
9/12/2014 4:30:00 PM - Zacks.com

Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog
9/11/2014 6:35:00 PM - Zacks.com

Medivation Eyes Blockbuster As Cancer Drug Gets An OK
9/11/2014 5:41:00 PM - Investor's Business Daily

Health Care Select Sector SPDR Fund Experiences Big Inflow
9/11/2014 11:42:08 AM - BNK Invest

Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
9/11/2014 9:45:03 AM - Motley Fool

Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
9/10/2014 5:20:00 PM - Zacks.com

Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog
9/10/2014 5:00:00 PM - Zacks.com

Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
9/10/2014 4:55:00 PM - Zacks.com

Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
9/10/2014 3:00:00 PM - Zacks.com

Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
9/10/2014 11:17:00 AM - Zacks.com